Mutation-based therapies for intrahepatic cholangiocarcinoma: new options on the horizon

Abstract

Intrahepatic cholangiocarcinoma (ICC), a rare but rising global malignancy originating from the bile ducts, poses significant challenges in terms of effective treatment and patient outcomes. While surgical excision remains the curative option, its limited efficacy necessitates more therapeutic strategies, including systemic therapies. The management of ICC involves a multidisciplinary approach, with treatment decisions guided by patient-specific and tumor-specific factors. Gemcitabine-cisplatin (GEMCIS) chemotherapy has been a standard first-line therapy, but recent advancements in immunotherapy, particularly the introduction of durvalumab, have provided new hope. Additionally, gene mutation-based therapies, targeting fibroblast growth factor receptors (FGFRs), isocitrate dehydrogenase-1 (IDH1), human epidermal growth factor receptor-2 (HER2), and B-RAF proto-oncogene (BRAF), offer promising prospects for personalized treatment. High-throughput genomic profiling technologies have facilitated the identification of actionable targets and the development of innovative therapeutic approaches. This review summarizes the mutation-based therapies in ICC, including FDA-approved targeted drugs and ongoing clinical trials, highlighting the evolving landscape of ICC treatment.

Keywords

Intrahepatic cholangiocarcinoma / mutation-based therapy / precision medicine

References

[1] Calderaro J,Zeng Q.Deep learning-based phenotyping reclassifies combined hepatocellular-cholangiocarcinoma.Nat Commun2023;14:8290 PMCID:PMC10719304

[2] Brindley PJ,Ilyas SI.Cholangiocarcinoma.Nat Rev Dis Primers2021;7:65 PMCID:PMC9246479

[3] Sung H,Siegel RL.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[4] Morgan E,Gini A.Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN.Gut2023;72:338-44

[5] Labib PL,Pereira SP.Molecular pathogenesis of cholangiocarcinoma.BMC Cancer2019;19:185 PMCID:PMC6394015

[6] Khan SA,Brandi G.Cholangiocarcinoma: epidemiology and risk factors.Liver Int2019;39 Suppl 1:19-31.

[7] Endo I,Yopp AC.Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.Ann Surg2008;248:84-96

[8] Mavros MN,Alexiou VG.Treatment and prognosis for patients with intrahepatic cholangiocarcinoma: systematic review and meta-analysis.JAMA Surg2014;149:565-74

[9] Bertuccio P,Carioli G.Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma.J Hepatol2019;71:104-14

[10] Woods E,Jakka BK.Changing landscape of systemic therapy in biliary tract cancer.Cancers2022;14:2137 PMCID:PMC9105885

[11] Moris D,Kim C,Morse MA.Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians.CA Cancer J Clin2023;73:198-222

[12] Valle J,Palmer DH.ABC-02 Trial InvestigatorsCisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.N Engl J Med2010;362:1273-81

[13] Vogel A,He AR.Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC).JCO2022;40:4075

[14] Oh D,Qin S.A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1.JCO2022;40:378

[15] Sia D,Moeini A.Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies.Oncogene2013;32:4861-70 PMCID:PMC3718868

[16] Saha SK,Kleinstiver BP.Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.Cancer Discov2016;6:727-39 PMCID:PMC5458737

[17] Jusakul A,Yong CH.Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma.Cancer Discov2017;7:1116-35 PMCID:PMC5628134

[18] Desjonqueres E,Marra F,Nault JC.Preneoplastic lesions in the liver: molecular insights and relevance for clinical practice.Liver Int2022;42:492-506

[19] van Dijk EL,Jaszczyszyn Y.Ten years of next-generation sequencing technology.Trends Genet2014;30:418-26

[20] De Luca A,Rachiglio AM.FGFR fusions in cancer: from diagnostic approaches to therapeutic intervention.Int J Mol Sci2020;21:6856 PMCID:PMC7555921

[21] Vogel A,Stenzinger A.FGFR2 inhibition in cholangiocarcinoma.Annu Rev Med2023;74:293-306

[22] Abou-Alfa GK,Javle MM.Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.Lancet Oncol2020;21:796-807 PMCID:PMC7523268

[23] Lowery MA,Janku F.Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.Lancet Gastroenterol Hepatol2019;4:711-20 PMCID:PMC7934945

[24] Javle M,Azad NS.Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study.Lancet Oncol2021;22:1290-300

[25] Harding J,Shapiro G.Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT ‘basket’ trial.Ann Oncol2019;30:iv127

[26] Babina IS.Advances and challenges in targeting FGFR signalling in cancer.Nat Rev Cancer2017;17:318-32

[27] Uson Junior PLS.Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.Expert Opin Investig Drugs2022;31:125-31

[28] Abou-Alfa GK,Hollebecque A.Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.Lancet Oncol2020;21:671-84 PMCID:PMC8461541

[29] Shi GM,Wen TF.Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: a phase II study.Cancer Med2023;12:4137-46

[30] Bekaii-Saab TS,Van Cutsem E.FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.Future Oncol2020;16:2385-99

[31] Javle M,Shroff RT.Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma.J Clin Oncol2018;36:276-82 PMCID:PMC6075847

[32] Javle M,Kelley RK.Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.Lancet Gastroenterol2021;6:803-15

[33] Makawita S,Roychowdhury S.Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.Future Oncol2020;16:2375-84

[34] Bahleda R,Goyal L.Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors.Ann Oncol2020;31:1405-12 PMCID:PMC9743148

[35] Goyal L,Hollebecque A.Updated results of the FOENIX-CCA2 trial: efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.J Clin Oncol2022;40:4009

[36] Borad MJ,Morizane C.A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 ( FGFR2 ) gene rearrangements (FOENIX-CCA3).JCO2020;38:TPS600

[37] Rizzo A,Brandi G.IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?.Cancer Treat Res Commun2021;27:100356

[38] Farshidfar F,Gingras MC.Cancer Genome Atlas NetworkIntegrative genomic analysis of cholangiocarcinoma identifies distinct idh-mutant molecular profiles.Cell Rep2017;18:2780-94 PMCID:PMC5493145

[39] Xiang X,Zhang C.IDH mutation subgroup status associates with intratumor heterogeneity and the tumor microenvironment in intrahepatic cholangiocarcinoma.Adv Sci2021;8:e2101230

[40] Lavacchi D,Rossi G.Ivosidenib in IDH1-mutated cholangiocarcinoma: clinical evaluation and future directions.Pharmacol Ther2022;237:108170

[41] Zhu AX,Javle MM.Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial.JAMA Oncol2021;7:1669-77

[42] Javle M,Jain A.Biliary cancer: utility of next-generation sequencing for clinical management.Cancer2016;122:3838-47

[43] Li M,Li X.Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway.Nat Genet2014;46:872-6

[44] Ramanathan RK,Singh DA.A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer.Cancer Chemother Pharmacol2009;64:777-83

[45] Peck J,Zalupski M,Villalona Calero M.HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib.Oncology2012;82:175-9

[46] Meric-Bernstam F,Hamilton E.Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.Lancet Oncol2022;23:1558-70

[47] Ohba A,Ueno M.Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.Future Oncol2022;18:2351-60

[48] Lee CK,Cheon J.Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean cancer study group (KCSG-HB19-14).Lancet Gastroenterol2023;8:56-65

[49] Xin HY,Zou JX.Association of BRAF variants with disease characteristics, prognosis, and targeted therapy response in intrahepatic cholangiocarcinoma.JAMA Netw Open2023;6:e231476 PMCID:PMC9984974

[50] Subbiah V,Élez E.Dabrafenib plus trametinib in patients with BRAF^V600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial.Lancet Oncol2020;21:1234-43

[51] Drilon A,Kummar S.Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children.N Engl J Med2018;378:731-9 PMCID:PMC5857389

[52] Doebele RC,Paz-Ares L.trial investigatorsEntrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.Lancet Oncol2020;21:271-82 PMCID:PMC7461630

[53] Jakubowski CD.Immune checkpoint inhibitor therapy in biliary tract cancer (cholangiocarcinoma).Chin Clin Oncol2020;9:2

[54] Fiste O,Gavriatopoulou M.The emerging role of immunotherapy in intrahepatic cholangiocarcinoma.Vaccines2021;9:422 PMCID:PMC8146949

[55] Jänne PA,Gadgeel SM.Adagrasib in non-small-cell lung cancer harboring a KRAS^G12C mutation.N Engl J Med2022;387:120-31

[56] Awad MM,Rybkin II.Acquired resistance to KRAS^G12C Inhibition in cancer.N Engl J Med2021;384:2382-93 PMCID:PMC8864540

[57] Sun J,Ma J.Notch-Sox9 axis mediates hepatocyte dedifferentiation in kras(G12V)-induced zebrafish hepatocellular carcinoma.Int J Mol Sci2022;23:4705 PMCID:PMC9103821

[58] Zhou SL,Sun RQ.Association of KRAS variant subtypes with survival and recurrence in patients with surgically treated intrahepatic cholangiocarcinoma.JAMA Surg2022;157:59-65 PMCID:PMC8567187

[59] Cox AD,Kimmelman AC,Der CJ.Drugging the undruggable RAS: mission possible?.Nat Rev Drug Discov2014;13:828-51 PMCID:PMC4355017

[60] Pylayeva-Gupta Y,Bar-Sagi D.RAS oncogenes: weaving a tumorigenic web.Nat Rev Cancer2011;11:761-74 PMCID:PMC3632399

[61] Blair HA.Sotorasib: first approval.Drugs2021;81:1573-9

[62] Skoulidis F,Dy GK.Sotorasib for lung cancers with KRAS p.G12C mutation.N Engl J Med2021;384:2371-81

[63] Sharma P,Wargo JA.Primary, adaptive, and acquired resistance to cancer immunotherapy.Cell2017;168:707-23 PMCID:PMC5391692

[64] Berchuck JE,DiToro DF.The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.Ann Oncol2022;33:1269-83

[65] Uson Junior PLS,Yin J.Cell-free tumor dna dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy.JCO Precis Oncol2022;6:e2100274 PMCID:PMC9200394

[66] Goyal L,Liu LY.Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma.Cancer Discov2017;7:252-63 PMCID:PMC5433349

[67] Silverman IM,Friboulet L.Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib.Cancer Discov2021;11:326-39

[68] Lau DK,Weickhardt A.Mechanisms of acquired resistance to fibroblast growth factor receptor targeted therapy.Cancer Drug Resist2019;2:568-79 PMCID:PMC8992533

[69] Lavacchi D,Palmieri VE.Immune checkpoint inhibitors in the treatment of renal cancer: current state and future perspective.Int J Mol Sci2020;21:4691 PMCID:PMC7369721

[70] Feng K,Zhao Y.Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.J Immunother Cancer2020;8:e000367 PMCID:PMC7269541

[71] Mohan A,Wuchu F.Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: preclinical evaluation and phase Ib multicenter clinical trial (BilT-04).Clin Cancer Res2023;29:2394-400 PMCID:PMC10330233

[72] Zeng TM,Lou C.Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer.Nat Commun2023;14:1340 PMCID:PMC10008621

[73] Lee HS,Cho K.Integrative analysis of multiple genomic data from intrahepatic cholangiocarcinoma organoids enables tumor subtyping.Nat Commun2023;14:237 PMCID:PMC9842736

[74] Bao X,Chen J.Molecular subgroups of intrahepatic cholangiocarcinoma discovered by single-cell RNA sequencing-assisted multiomics analysis.Cancer Immunol Res2022;10:811-28

[75] Dong L,Chen R.Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.Cancer Cell2022;40:70-87.e15